Table 1.
Baseline characteristics for patients in the acupuncture and usual care groups
| Characteristics | Acupuncture (n = 20), n (%) | Usual care (n = 20), n (%) |
|---|---|---|
| Age, median (range), years | 54.0 (32.0–68.0) | 53.5 (26.0–71.0) |
| Months between Dx and enrollment, median (range) | 17.3 (1.4–92.0) | 13.3 (5.3–92.4) |
| Sex: female | 20 (100) | 20 (100) |
| Race | ||
| White | 16 (80) | 15 (75) |
| Black | 2 (10) | 3 (15) |
| Asian | 2 (10) | 2 (10) |
| Stages | ||
| I | 4 (20) | 7 (35) |
| II | 11 (55) | 5 (25) |
| III | 5 (25) | 8 (40) |
| Hormone receptor status | ||
| ER− | 7 (35) | 6 (30) |
| ER+ | 13 (65) | 14 (70) |
| PR− | 7 (35) | 12 (60) |
| PR+ | 13 (65) | 8 (40) |
| Prior therapies | ||
| Mastectomy | 9 (45) | 9 (45) |
| Breast conservation | 11 (55) | 11 (55) |
| Anthracycline | 18 (90) | 13 (65) |
| Taxane | 20 (100) | 20 (100) |
| Trastuzumab | 6 (30) | 5 (25) |
| Radiation | 14 (70) | 17 (85) |
| Hormonal therapy | 11 (55) | 10 (50) |
| Pretreatment NCI‐CTCAE neuropathy grade | ||
| Grade 1 | 9 (45) | 9 (45) |
| Grade 2 | 9 (45) | 8 (40) |
| Grade 3 | 1 (5) | 0 (0) |
| Missing | 1 (5) | 3 (15) |
Abbreviations: Dx, last chemotherapy; ER, estrogen receptor; NCI‐CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; PR, progesterone receptor.